Q-omics provides the consensus-scored STAMBP profile across patient tissues and cancer cell-line models. STAMBP expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, STAMBP is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, STAMBP RNA expression shows 20,172 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where STAMBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STAMBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STAMBP survival associations across molecular data types. STAMBP RNA expression shows survival associations in the most cancer types (30), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STAMBP RNA expression–survival associations across cancer types. High STAMBP expression shows unfavorable associations in ACC, LIHC, KIRP and UCEC, but favorable associations in KIRC and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for STAMBP RNA expression.
This table summarizes STAMBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for STAMBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STAMBP shows lower tumor expression in THCA and higher tumor expression in HNSC, BLCA, LUAD, KIRC and LIHC. The HNSC box plot shows higher STAMBP RNA expression in tumor versus normal tissue (log2 FC = +0.869, t-test p < 0.001).
This table shows molecular features associated with STAMBP in patient tissues and cancer cell lines. In patient samples, STAMBP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, STAMBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
